Clinical Report: DNER Modulates Glycolytic Metabolism in Renal Cell Carcinoma
Overview
This study identifies DNER as a key regulator of glycolytic metabolism in clear cell renal cell carcinoma (ccRCC) through the JAK2/STAT3 signaling pathway. DNER's role in promoting tumor cell proliferation and influencing immune cell polarization highlights its potential as a therapeutic target.
Background
Clear cell renal cell carcinoma (ccRCC) is a prevalent malignancy with a high mortality rate, often diagnosed at advanced stages. The disease is characterized by unique metabolic reprogramming that contributes to tumor progression and immune evasion. Understanding the molecular mechanisms underlying ccRCC is crucial for developing effective therapeutic strategies.
Data Highlights
No numerical data or trial data presented in the source.
Key Findings
DNER is identified as a hub gene associated with metabolic pathway activity and immune cell infiltration in ccRCC.
DNER promotes ccRCC cell proliferation in both in vitro and in vivo models.
DNER activates the JAK2/STAT3 signaling pathway, leading to increased expression of glycolytic enzymes LDHA and PKM.
Enhanced glycolytic flux results in increased lactate production, which drives macrophage polarization towards a pro-tumorigenic M2-like phenotype.
DNER overexpression may correlate with increased sensitivity of ccRCC cells to the PARP inhibitor Olaparib.
Clinical Implications
The findings suggest that targeting DNER could be a potential therapeutic strategy in ccRCC. Understanding the role of DNER in metabolic reprogramming may inform treatment approaches that address both tumor growth and immune evasion.
Conclusion
DNER plays a significant role in ccRCC progression by linking glycolytic metabolism to immune microenvironment changes, indicating its potential as a therapeutic target.
